United States· US:69448-017_450dafe8-f537-6303-e063-6394a90aa784
IMULDOSA
A interleukin inhibitors product containing ustekinumab-srlf, registered in United States by Accord BioPharma Inc.. The same ATC class is registered in 3 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Ustekinumab-srlf is registered in 3 of 19 countries.
Countries holding a registration under ATC L04AC (interleukin inhibitors), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 2 of them publish a price we can compare per daily dose
Ustekinumab-srlf · ATC L04AC
3 / 19 countries
- Belgiumprice
- Ireland
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- ustekinumab-srlf
- Manufacturer
- Accord BioPharma Inc.
- Country
- United States (US)
- ATC code
- L04AC
- ATC class
- Interleukin inhibitors
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- June 3, 2026
Packs & prices · 1
- ndc1169448017631 BLISTER PACK in 1 CARTON (69448-017-63) / 1 SYRINGE in 1 BLISTER PACK / .5 mL in 1 SYRINGE
Regulatory notes
Same medicine, other countries
Ustekinumab-srlf in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandABSIMKYAccord Healthcare S.L.U.
- BelgiumAbsimky 130 mgAccord Healthcare
- CzechiaFYMSKINAFormycon AG, Martinsried/Planegg
- SwedenFymskina 130 mg Koncentrat till infusionsvätska, lösningFormycon AG
- PolandAbsimkyAccord Healthcare S.L.U.
- IcelandFymskinaFormycon AG
- NetherlandsFymskina 130 mg concentraat voor oplossing voor infusieFormycon AG
- IrelandFymskina 130 mg Concentrate for solution for infusionFormycon AG
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Imuldosa, Uzpruvo
- Iceland · Fymskina, Imuldosa
- Liechtenstein · Fymskina, Imuldosa
- Norway · Fymskina, Imuldosa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/103976dc-6793-49f9-a603-00704b7fa86f GET /v1/drugs/103976dc-6793-49f9-a603-00704b7fa86f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"spl_meta": {
"2539a6cf-0fe5-1565-e063-6294a90a3618": {
"match": "brand_token",
"title": "IMULDOSA (USTEKINUMAB-SRLF) INJECTION [ACCORD BIOPHARMA INC.]",
"spl_version": "9",
"published_date": "2025-12-04"
}
},
"productid": "69448-017_450dafe8-f537-6303-e063-6394a90aa784",
"productndc": "69448-017",
"dosage_form": "INJECTION",
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "USTEKINUMAB-SRLF",
"proprietary_name": "IMULDOSA",
"active_ingred_unit": "mg/.5mL",
"application_number": "BLA761364",
"marketing_category": "BLA",
"nonproprietary_name": "ustekinumab-srlf",
"start_marketing_date": "20241014",
"active_numerator_strength": "45"
}See everything about ustekinumab-srlf.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.